<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00201708</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-0450</org_study_id>
    <nct_id>NCT00201708</nct_id>
  </id_info>
  <brief_title>Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer</brief_title>
  <official_title>Phase II Randomized Adjuvant Trial of Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide (AC) in Axillary Node-Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine if docetaxel will be administered before or after
      doxorubicin/cyclophosphamides in an adjuvant chemotherapy regimen to be evaluated in a
      subsequent phase III trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Studies suggest that chemotherapy agents docetaxel, doxorubicin, and
      cyclophosphamide have some efficacy against different types of breast cancer. However, the
      optimal sequence in which to administer these treatments remains unknown. The current study
      assesses two separate sequences of docetaxel, doxorubicin, and cyclophosphamide.

      Purpose: This study will evaluate two different combination chemotherapy schedules for
      patients with axillary node-positive breast cancer. Combination one is docetaxel before
      doxorubicin and cyclophosphamide. Combination two is docetaxel after doxorubicin and
      cyclophosphamide. The combination with no dose reductions of docetaxel within 10 weeks will
      then be tested in a Phase III study. The toxicities of docetaxel will also be assessed in
      study participants.

      Treatment: Patients in this study will receive one of two chemotherapy combination schedules.
      A computer will randomly assign patients into their treatment group. Group one will receive
      docetaxel before doxorubicin and cyclophosphamide. Group two will receive docetaxel after
      doxorubicin and cyclophosphamide.

      Patients in group one will receive docetaxel every two weeks for a total of eight weeks.
      These patients will then be given combination doxorubicin and cyclophosphamide every two
      weeks for a total of eight weeks. Patients in group two will receive combination doxorubicin
      and cyclophosphamide every two weeks for a total of eight weeks. These patients will then be
      given docetaxel every two weeks for a total of eight weeks.

      Several tests and exams will be given throughout the study to closely monitor patients.
      Treatments will be discontinued due to disease growth or unacceptable side effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Select one of two adjuvant chemotherapy regimens for evaluation in subsequent phase III trial.</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>Docetaxel before doxorubicin/cyclophosphamide(AC)or Docetaxel after AC. The regimen selection will be based on the proportion of patients receiving four cycles of Docetaxel with no dose reductions within 10 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the toxicities of Docetaxel administered before or after doxorubicin/cyclophosphamide(AC).</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A (Docetaxel before doxorubicin/cyclophosphamide)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel 75 mg/m2 every 2 weeks for 4 cycles followed by &quot;A&quot; (doxorubicin) 60 mg/m2 &amp; &quot;C&quot; (cyclophosphamide) 600 mg/m2 every 2 weeks for 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Docetaxel after doxorubicin/cyclophosphamide)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>&quot;A&quot; (doxorubicin) 60 mg/m2 &amp; &quot;C&quot; (cyclophosphamide) 600 mg/m2 every 2 weeks for 4 cycles followed by Docetaxel 75 mg/m2 every 2 weeks for 4 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Arm A:75 mg/m2 every 2 weeks)for 4 cycles. Arm B:75 mg/m2 every 2 weeks for 4 cycles.</description>
    <arm_group_label>Arm A (Docetaxel before doxorubicin/cyclophosphamide)</arm_group_label>
    <arm_group_label>Arm B (Docetaxel after doxorubicin/cyclophosphamide)</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>60 mg/m2 intravenously as push over 2-5 minutes, every 14 days for 4 cycles. Arms: Arm A (Docetaxel before doxorubicin/cyclophosphamide) , Arm B (Docetaxel after doxorubicin/cyclophosphamide)</description>
    <arm_group_label>Arm A (Docetaxel before doxorubicin/cyclophosphamide)</arm_group_label>
    <arm_group_label>Arm B (Docetaxel after doxorubicin/cyclophosphamide)</arm_group_label>
    <other_name>Adriamycin</other_name>
    <other_name>hydroxydaunorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide (AC)</intervention_name>
    <description>600 mg/m2 over 30 to 60 minutes every 14 days (2 weeks) for 4 cycles. Arms: Arm A (Docetaxel before doxorubicin/cyclophosphamide), Arm B (Docetaxel after doxorubicin/cyclophosphamide)</description>
    <arm_group_label>Arm A (Docetaxel before doxorubicin/cyclophosphamide)</arm_group_label>
    <arm_group_label>Arm B (Docetaxel after doxorubicin/cyclophosphamide)</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>CYT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have histologically or cytologically confirmed breast cancer

          -  No metastatic disease

          -  Prior lumpectomy or mastectomy

          -  No prior chemotherapy or hormone treatments for breast cancer

          -  Must have normal organ and marrow function.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

        Exclusion Criteria:

          -  Peripheral neuropathy of grade II or higher.

          -  History or evidence upon physical exam of CNS (central nervous system
             Diseases)disease.

          -  History of unstable angina or myocardial infarction within the last six months.

          -  Pregnant or nursing women.

          -  Known allergies to polysorbate 80.

          -  HIV-positive patients.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Shapiro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>Jamesline</description>
  </link>
  <reference>
    <citation>Puhalla S, Mrozek E, Young D, Ottman S, McVey A, Kendra K, Merriman NJ, Knapp M, Patel T, Thompson ME, Maher JF, Moore TD, Shapiro CL. Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer. J Clin Oncol. 2008 Apr 1;26(10):1691-7. doi: 10.1200/JCO.2007.14.3941. Epub 2008 Mar 3.</citation>
    <PMID>18316792</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>September 1, 2016</last_update_submitted>
  <last_update_submitted_qc>September 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adjuvant Trial</keyword>
  <keyword>Dose-Dense</keyword>
  <keyword>Axillary Node-Positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

